Diana Bilton

List of Publications by Year in Descending Order

74 papers	3,677 citations	29 h-index	60 g-index
89 ext. papers	4,537 ext. citations	6.1 avg, IF	5.17 L-index

#	Paper	IF	Citations
74	Heterogeneity of treatment response in bronchiectasis clinical trials. *European Respiratory Journal*, **2021**,	13.6	3
73	Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection. *Journal of Cystic Fibrosis*, **2021**, 20, 1010-1017	4.1	3
72	Long-term safety study of colistimethate sodium (Colobreathe): Findings from the UK Cystic Fibrosis Registry. *Journal of Cystic Fibrosis*, **2021**, 20, 324-329	4.1	3
71	Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. *Journal of Cystic Fibrosis*, **2021**,	4.1	4
70	The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. *Scientific Reports*, **2020**, 10, 10660	4.9	3
69	Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. *Journal of Cystic Fibrosis*, **2020**, 19, 68-79	4.1	76
68	Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 284-291	4.1	19
67	Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis. *BMJ Open Respiratory Research*, **2019**, 6, e000399	5.6	5
66	Results from an online survey of adults with cystic fibrosis: Accessing and using life expectancy information. *PLoS ONE*, **2019**, 14, e0213639	3.7	5
65	The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study. *PLoS ONE*, **2019**, 14, e0212779	3.7	24
64	Investigating the effects of long-term dornase alfa use on lung function using registry data. *Journal of Cystic Fibrosis*, **2019**, 18, 110-117	4.1	8
63	Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry. *Journal of Cystic Fibrosis*, **2019**, 18, 665-670	4.1	13
62	The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice. *Medical Mycology*, **2019**, 57, 155-160	3.9	14
61	Laboratory Diagnosis and Characterization of Fungal Disease in Patients with Cystic Fibrosis (CF): A Survey of Current UK Practice in a Cohort of Clinical Microbiology Laboratories. *Mycopathologia*, **2018**, 183, 723-729	2.9	6
60	Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. *Journal of Cystic Fibrosis*, **2018**, 17, 218-227	4.1	90
59	Data Resource Profile: The UK Cystic Fibrosis Registry. *International Journal of Epidemiology*, **2018**, 47, 9-10e	7.8	40
58	Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations. *Journal of Cystic Fibrosis*, **2017**, 16, 36-40	4.1	20

57	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. *Journal of Cystic Fibrosis*, **2017**, 16, 695-701	4.1	2
56	adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. *European Respiratory Journal*, **2017**, 49,	13.6	46
55	Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. *Clinical and Translational Science*, **2017**, 10, 28-34	4.9	33
54	HbA1c as a screening tool for cystic fibrosis related diabetes. *Journal of Cystic Fibrosis*, **2016**, 15, 251-7	4.1	30
53	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. *Science*, **2016**, 354, 751-757	33.3	314
52	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. *Thorax*, **2016**, 71, 88-90	7.3	118
51	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. *Thorax*, **2016**, 71 Suppl 1, i1-22	7.3	230
50	Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 744-51	5.9	69
49	Response to Letter to the Editor: HbA1c as a screening tool for cystic fibrosis related diabetes: Response to letters by Widger et al. and Schnyder et al. *Journal of Cystic Fibrosis*, **2016**, 15, 265-6	4.1	1
48	Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis. *European Respiratory Journal*, **2015**, 46, 262-4	13.6	18
47	Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. *Respiratory Medicine*, **2015**, 109, 357-63	4.6	14
46	A new chapter in therapy for cystic fibrosis. *Lancet Respiratory Medicine,the*, **2015**, 3, e20	35.1	2
45	Effective strategies for managing new Pseudomonas cultures in adults with cystic fibrosis. *European Respiratory Journal*, **2015**, 46, 862-5	13.6	6
44	The reproducibility and responsiveness of the lung clearance index in bronchiectasis. *European Respiratory Journal*, **2015**, 46, 1645-53	13.6	23
43	Children and young adults with CF in the USA have better lung function compared with the UK. *Thorax*, **2015**, 70, 229-36	7.3	41
42	S55 Towards the Clinical Application of Anti-pseudomonal Bacteriophage: Activity is Retained Following Nebulisation with a Range of Commercially Available Nebuliser Systems. *Thorax*, **2015**, 70, A34.1-A34	7.3	1
41	Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis. *BMC Pulmonary Medicine*, **2015**, 15, 151	3.5	15
40	P220 Using funnel plots to make meaningful centre comparisons. *Thorax*, **2015**, 70, A187.2-A188	7.3	

39	USE OF APREPITANT AS AN ANTIEMETIC IN CYSTIC FIBROSIS PATIENTS. *BMJ Supportive and Palliative Care*, **2015**, 5, 118.2-119	2.2	
38	Optimising inhaled mannitol for cystic fibrosis in an adult population. *Breathe*, **2015**, 11, 39-48	1.8	18
37	Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. *Journal of Cystic Fibrosis*, **2015**, 14, 632-8	4.1	15
36	Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. *Thorax*, **2014**, 69, 1073-9	7.3	108
35	Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. *Respiratory Medicine*, **2014**, 108, 1397-408	4.6	47
34	Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 975-82	10.2	187
33	S66 The Gli Spirometry Reference Equations Influence The Apparent Rate Of Decline In Fev1 Among Children And Adolescents With Cystic Fibrosis. *Thorax*, **2014**, 69, A37-A37	7.3	
32	The expanding armamentarium of drugs to aid sputum clearance: how should they be used to optimize care?. *Current Opinion in Pulmonary Medicine*, **2014**, 20, 601-6	3	11
31	Personalised medicine in cystic fibrosis must be made affordable. *Paediatric Respiratory Reviews*, **2014**, 15 Suppl 1, 6-7	4.8	3
30	BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. *Journal of Cystic Fibrosis*, **2014**, 13, 156-63	4.1	47
29	Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. *Journal of Cystic Fibrosis*, **2013**, 12, 130-40	4.1	106
28	Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. *Journal of Cystic Fibrosis*, **2013**, 12, 367-76	4.1	53
27	Azithromycin in bronchiectasis: evidence in children?. *Lancet Respiratory Medicine,the*, **2013**, 1, 587-589	35.1	
26	P100 Successful eradication of respiratory tract MRSA in cystic fibrosis: a retrospective study. *Thorax*, **2013**, 68, A120.1-A120	7.3	
25	Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. *Chest*, **2013**, 144, 215-225	5.3	74
24	P175 The Short Term Variability of Sputum Microbiology in Non-CF Bronchiectasis. *Thorax*, **2012**, 67, A139.1-A139	7.3	
23	S103 Anti-Pseudomonal Bacteriophage Cocktail Reduces Inflammatory Responses in the Murine Lung. *Thorax*, **2012**, 67, A50.3-A51	7.3	1
22	S122 Is There a Gender Difference in the UK CF Population?. *Thorax*, **2012**, 67, A59.1-A59	7.3	

21	S123 The Role of Nasal Potential Difference Testing in Difficult Cases of Possible Cystic Fibrosis. *Thorax*, **2012**, 67, A59.2-A59	7.3	
20	Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. *Journal of Cystic Fibrosis*, **2011**, 10 Suppl 2, S79-81	4.1	126
19	Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. *BMJ, The*, **2011**, 342, d1008	5.9	84
18	Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. *European Respiratory Journal*, **2011**, 38, 1071-80	13.6	117
17	P236 Cystic Fibrosis deaths in USA and UK: comparisons of registry and routine data. *Thorax*, **2011**, 66, A163-A164	7.3	1
16	S48 Mucoidy and the microbiome: community composition in relation to the presence of culturable, mucoid Pseudomonas aeruginosa. *Thorax*, **2011**, 66, A24-A24	7.3	1
15	P227 Disparities in care of adult CF patients in the UK. *Thorax*, **2010**, 65, A172-A173	7.3	
14	P103 Oral contraceptive use does not affect CF disease severity. *Thorax*, **2010**, 65, A121-A121	7.3	
13	British Thoracic Society guideline for non-CF bronchiectasis. *Thorax*, **2010**, 65 Suppl 1, i1-58	7.3	625
12	Update on non-cystic fibrosis bronchiectasis. *Current Opinion in Pulmonary Medicine*, **2008**, 14, 595-9	3	55
11	Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. *Chest*, **2006**, 130, 1503-10	5.3	121
10	Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. *Journal of Antimicrobial Chemotherapy*, **2005**, 55, 921-7	5.1	137
9	Nurse specialist care for bronchiectasis. *The Cochrane Library*, **2003**,	5.2	11
8	Knowledge of pancreatic enzyme supplementation in adult cystic fibrosis (CF) patients. *Journal of Human Nutrition and Dietetics*, **2000**, 13, 353-361	3.1	4
7	Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. *American Journal of Respiratory Cell and Molecular Biology*, **1998**, 18, 670-4	5.7	121
6	Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. *BMJ: British Medical Journal*, **1998**, 316, 1771-5		156
5	Structural explanation for the deficiency of S alpha 1-antitrypsin. *Nature Structural Biology*, **1996**, 3, 910-1		76
4	The isolation and characterization of non-typeable Haemophilus influenzae from the sputum of adult cystic fibrosis patients. *European Respiratory Journal*, **1995**, 8, 948-53	13.6	11

3	Placebo-Controlled Trials of Antioxidant Therapy Including S-Adenosylmethionine in Patients with Recurrent Nongallstone Pancreatitis. *Drug Investigation*, **1994**, 8, 10-20		34
2	Cholecystectomy as the treatment of choice in cystic fibrosis. *American Journal of Surgery*, **1990**, 160, 323-4	2.7	1
1	Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-CF bronchiectasis patients		2